Skip to content
★ Sign in to follow
JS

Jiangxi Sanxin Medtec Co.,Ltd. Stock: price and insider trades · China

三鑫医疗

CN·Mcap CN¥4.8BHealth Care

No insider purchase over the last 90 days. The latest, by 彭义兴, was filed 09 Jun 2026.

Jiangxi Sanxin Medtec Co.,Ltd.: what insiders have been doing

Every trade that managers of Jiangxi Sanxin Medtec Co.,Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector. In the past year (7 November 2025 to 7 November 2026), 1 filing came from 1 insider.

Every open-market trade in the period is a purchase: 1 purchase worth €16k, from 1 insider, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. At €16k, the purchase published on 9 June 2026 by 彭义兴 is the largest of the period. Those buying include 1 chief executive.

Compared with its exchange (522 companies, median 2 filings), a count of 1 filing is below the norm. Looking back to 2021, when coverage begins, insiders filed 2 purchases and no sales.

The clock since the last published purchase (9 June 2026) now reads 152 days.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Insider Decl.
2
Thresholds
n/a
Buy Volume
€136,515
2 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
彭义兴1 buy

Since the insiders bought

  • Filed 09 Jun 2026 · 152 days ago · €16k
    +8.2%
    Entry CN¥9.00 · Close 05 Nov 2026 CN¥9.74
  • Filed 02 Nov 2021 · 1832 days ago · €121k
    -26.9%
    Entry CN¥9.29 · Close at T+365 CN¥6.79

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 5,336 of 26,911 companies
67.1
score / 100
Value
59
Quality
76
FCF yld4.5%
Earn yld5.5%
EV/EBITDA11.3x
ROE20%
Gross mgn36%
Net mgn16%
Debt/EBITDA0.5x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥9.25
Analyst consensus
·
Income statement
RevenueCN¥1.6B
Gross profitCN¥590.9M36% margin
EBITDACN¥447.5M27% margin
Net incomeCN¥264.9M16.3% margin
Valuation
PER (trailing)16.2x
P/Book3.1x
Beta0.14
Balance sheet & cash
Market capCN¥4.8B
Total debtCN¥230M
Free Cash FlowCN¥218.7M
Debt / Equity44%
Profitability & ownership
ROE20.3%
ROA7.7%
% insiders49.1%
% institutions3.0%
Last declaration on 9 June 2026
Declarations2 total
  • ▲
    董事长Executives
    123,200 CNY30SZSE
    14,000 shares@ CN¥68.7484100.0% of flowA股XSHESZSE:273000000697735600
    Canonical exit: 7 Sept 2026 (T+90)
  • ▲
    监事Executives
    897,260 CNY15SZSE
    75,400 shares100.0% of flowA股XSHESZSE:173000005034219940
    Canonical exit: 31 Jan 2022 (T+90)

2 of 2 declarations

About Jiangxi Sanxin Medtec Co.,Ltd.

三鑫医疗 is a company in the healthcare and pharmaceutical sector, listed on the XSHE market. It focuses on the development and manufacturing of medical devices and health solutions.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations